We collected 14 patients with EG from 105 patients diagnosed with PLELC from January 2013 to December 2018, and their clinicopathological characteristics and treatment was analyzed.
followed-up 15 months (10-31 months). The median age was 48.5 yearold (38-67 year-old) and 85.7% of them were under the age of 60, meanwhile females had a slightly higher proportion than males (1.8:1). Most patients were at early stage (71.4%) with nonspecific manifestations such as cough, expectoration and lack of rich-lewis phenomenon. EG was often located in tumor or beside the tumor (71.4%), which was all negative in specific stain of pathology. In situ hybridization of EBV-encoded RNA (EBER) was all positive. In our group, there were 2 patients received palliative chemotherapy (the duration of progression-free survival were 8 and 10 months, respectively). Twelve of them underwent surgical resection including 10 with adjuvant or neoadjuvant chemotherapy, of which two had disease relapsed in 8 and 25 months after surgery. None of them had tuberculosis occur, progression or relapse, even if antituberculosis therapy were not taken.
Conclusion: PLELC with EG was lack of specific clinical characteristic compared with the patients without EG. It is important for us to make an exact pathological diagnosis, and attentions should be paid to obtain samples by biopsy and make differential diagnosis. PLELC with EG could receive multimodality therapy such as chemotherapy, and antituberculosis therapy was not necessary. The formation of EG may be caused by immunological hypersensitivity to tumor cell or EBV infection instead of tuberculosis. and Paclitaxel (PTX) was appealing for basic and clinical exploration due to a distinct mechanism of action and non-overlapping toxicities. This study aims to elucidate a potential effect of GEM in combination with PTX.
Methods: To determine half inhibition concentration (IC 50 ), two nonsmall cell lung cancer (NSCLC) cell lines, A549 and H520 were treated with GEM and PTX for 48 h. With a constant ratio of IC 50 , simultaneous exposure of cell lines to drugs by the sequence as follows: GEM!PTX, vice versa PTX!GEM, or GEM and PTX simultaneously (GEM+PTX) to analysis combination Index (CI). Western blot in determining GEM`s effect on acetylation of tubulin Results: IC 50 of GEM in A549 and H520 were 6.6nM and 46.1nM, respectively. IC 50 of PTX in A549 and H520 were 1.35nM and 7.59nM, respectively. The sequence of GEM!PTX in A549 and H520 resulted in slight synergism and strong synergism, respectively. Immunoblotting showed intense expressions band of acetylated tubulin protein in both cell lines in the sequence GEM!PTX.
Conclusion: GEM enhances anti-tumor activity of PTX via modulating tubulin acetylation. GEM!PTX sequence may be a promising candidate regimen against NSCLC. 
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Background and Aims: Tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, and afatinib are recommended as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations. However, few studies compared these three TKIs together.
Methods:
We conducted a retrospective cohort study using database from the claims database of Taipei Veterans General Hospital, a medical center in Taiwan. New or recurrent stage IIIb and IV NSCLC patients with EGFR mutations receiving more than 3 months as first-line treatment from 2011 to 2016 were enrolled. Primary endpoint was progression-free survival and observation period was 2 years. Secondary endpoint was allcause mortality. Patients using co-medications at least 28 defined daily dose in first three months of TKIs therapy were assigned to comedications groups.
Results: A total of 853 subjects (gefitinib: 534, erlotinib: 220, afatinib: 99) were enrolled in the study. The median duration of progression-free survival was 11.5 months in the gefitinib arm, 11.7 months in the erlotinib arm, and 16.1 months in the afatinib arm (log-rank test, P < 0.001). After adjusting for age, sex, EGFR mutation status, lung cancer stage, ECOG performance status, smoking status, radiotherapy, baseline brainmetastases, Charlson Comorbidity Index, co-medications, afatinib showed lower progression risk compared with gefitinib (hazard ratio
[HR] = 0.54, 95%CI = 0.41-0.71) and erlotinib (HR = 0.62, 95% CI = 0.46-0.83). HR of progression for TKI users received systemic steroids were higher than TKI alone users (HR = 1.47, 95% CI = 1.08-2.01). Overall survival was significantly longer in the patients who received afatinib or erlotinib compared to those who received gefitinib. In the section of brain metastases, there was no significant difference among three TKIs.
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